产品详情
简单介绍：
Anti-PCDH1抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-PCDH1抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
详情介绍：
Rabbit Anti-PCDH1
Cat. Number:
Anti-PCDH1抗体KL-11111R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Protocadherins are a subfamily of cadherins, a large group of related glycoproteins that mediate calcium-dependent cell-to-cell adhesion via a homophilic mechanism. Involved in a variety of functions, protocadherins help Anti-PCDH1抗体to regulate neural development and synapse formation. PCDH1 is a 1,026 amino acid single-pass type I membrane protein that contains seven cadherin domains and is a member of the protocadherin family. Localized to cell-cell and cell-matrix boundaries and expressed at high levels in brain and neuro-glial cells, PCDH1 is thought to be involved in cell adhesion and cell-cell interactions and may play a role in neuronal development. PCDH1 contains a C-terminal cytoplasmic region, an extracellular region and a transmembrane region, and is expressed as two isoforms due to alternative splicing events.
Also known as:
Cadherin like 1; Cadherin like protein 1; Anti-PCDH1抗体PC 42; PC42; PCDH 1; PCDH-1; PCDH 42; PCDH42; Protocadherin 1; Protocadherin 42; Protocadherin1; Protocadherin42.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, .
●
Immunogen: KLH conjugated syntheticAnti-PCDH1抗体 peptide derived from human PCDH1.
●
Predicted Molecular Weight: 110kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-PCDH1抗体
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
